Older men who hip fracture experience greater declines in BMD in contralateral hip than non-fractured men

Men experience declining bone mineral density (BMD) after hip fracture; however, changes attributable to fracture are unknown. This study evaluated the excess BMD decline attributable to hip fracture among older men. Older men with hip fracture experienced accelerated BMD declines and are at an increased risk of secondary fractures.

Two cohorts were used: Baltimore Hip Studies 7th cohort (BHS-7) and Baltimore Men’s Osteoporosis Study (MOST). BHS-7 recruited older adults (N = 339) hospitalized for hip fracture; assessments occurred within 22 days of admission and at 2, 6, and 12 months follow-up. MOST enrolled age-eligible men (N = 694) from population-based listings; data were collected at a baseline visit and a second visit that occurred between 10 and 31 months later. The combined sample (n = 452) consisted of Caucasian men from BHS-7 (n = 89) and MOST (n = 363) with ≥ 2 dual-energy X-ray absorptiometry scans and overlapping ranges of age, height, and weight. Mixed-effect models estimated rates of BMD change, and generalized linear models evaluated differences in annual bone loss at the total hip and femoral neck between cohorts.

Adjusted changes in total hip and femoral neck BMD were – 4.16% (95% CI, – 4.87 to – 3.46%) and – 4.90% (95% CI, – 5.88 to – 3.92%) in BHS-7 participants; – 1.57% (95% CI, – 2.19 to – 0.96%) and – 0.99% (95% CI, – 1.88 to – 0.10%) in MOST participants; and statistically significant (P < 0.001) between-group differences in change were – 2.59% (95% CI, – 3.26 to – 1.91%) and – 3.91% (95% CI, – 4.83 to – 2.98%), respectively.

Hip fracture in older men is associated with accelerated BMD declines at the non-fractured hip that are greater than those expected during aging, and pharmacological interventions in this population to prevent secondary fractures may be warranted.

Gluteal tendinopathy

Join Alison Grimaldi and Bill Vicenzino in this short online course for a review of the results and clinical implications of the LEAP trial.